ASSA13-16-6 The Increased Circulatory RAS Activity Can Be Inhibited by Statins
ObjectiveTo investigate the profile of circulatory renin-angiotensin system (RAS) activity in hypercholesterolemia (HC) patients treated with statins. Methods This study included 18 primary HC patients and 18 sex-and age-matched healthy adults. Total cholesterol (TC), triglyceride (TG), LDL-C and bl...
Gespeichert in:
Veröffentlicht in: | Heart (British Cardiac Society) 2013-04, Vol.99 (Suppl 1), p.A77-A78 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | A78 |
---|---|
container_issue | Suppl 1 |
container_start_page | A77 |
container_title | Heart (British Cardiac Society) |
container_volume | 99 |
creator | Hai, Su Weitong, Hu Qiang, Peng Dezhi, Hong Jianyong, Ma Qing, Yang Xiaoshu, Cheng |
description | ObjectiveTo investigate the profile of circulatory renin-angiotensin system (RAS) activity in hypercholesterolemia (HC) patients treated with statins. Methods This study included 18 primary HC patients and 18 sex-and age-matched healthy adults. Total cholesterol (TC), triglyceride (TG), LDL-C and blood glucose, angiotensin-converting enzyme (ACE) activity and angiotensin II (AngII) levels were measured at baseline. These parameters were measured again at 4 and 8 weeks after statin treatment in HC group respectively. Results At baseline, the TC, TG and LDL-C, as well as ACE activity and AngII level, were significantly higher in HC group. On the baseline data of 36 participates, significant positive correlations existed between ACE activity and TC(r = 0.54) or LDL-C(r = 0.51), and between AngII level and TC(r = 0.34) or LDL-C(r = 0.27). In HC patients, 8 weeks statin treatment significantly decreased TC, LDL-C, as well as Ang II (35.46 ± 14.49 vs 71.10 ± 20.47 pg/ml, P < 0.05) levels and ACE activity (108.9 ± 51.9vs 180.1 ± 71.3 U/L, P < 0.05), meanwhile, positive correlations between RAS activity and TC or LDL-C levels measured before and after treatment were seen in HC patients. Conclusions Serum cholesterol-lowering with statins is associated with decreasing circulatory RAS activity in hypercholesterolemia patients. |
doi_str_mv | 10.1136/heartjnl-2013-303992.240 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1780727544</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4021078231</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1594-511bc80752c25ef381d60a93d7da3180e6e36d80d9e0a519a4b3b619be53b31a3</originalsourceid><addsrcrecordid>eNqNkMtOwzAQRSMEEqXwD5FYp3gysZMsQwS0UsWrpWJn2YmrJrRJsV1Edmz4Ub4EVwHWrGY0OveOdDzPBzICQHaxUkLbulkHIQEMkGCahqMwIgfeACKW7M_Ph25HSgNGMD72ToypCSFRmrCBd5_NZpkLAgvY18fnfKX8SVNoJYwq_bzSxW4tbKs7_zGb-Vlhq7fKdn4uGv9yT64qWVlHys6fWWGrxpx6R0uxNursZw69p-ureT4Opnc3kzybBhJoGgUUQBYJiWlYhFQtMYGSEZFiGZcCISGKKWRlQspUEUEhFZFEySCViqJEEDj0zvverW5fd8pYXrc73biXHGJXHMY0ihyV9FShW2O0WvKtrjZCdxwI3_vjv_743h_v_XHnz0WDPloZq97_ckK_cBZjTPntIudjmF8v8IHyxPHY83JT___LNwyhgxY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1780727544</pqid></control><display><type>article</type><title>ASSA13-16-6 The Increased Circulatory RAS Activity Can Be Inhibited by Statins</title><source>PubMed Central Free</source><source>BMJ Journals - NESLi2</source><creator>Hai, Su ; Weitong, Hu ; Qiang, Peng ; Dezhi, Hong ; Jianyong, Ma ; Qing, Yang ; Xiaoshu, Cheng</creator><creatorcontrib>Hai, Su ; Weitong, Hu ; Qiang, Peng ; Dezhi, Hong ; Jianyong, Ma ; Qing, Yang ; Xiaoshu, Cheng</creatorcontrib><description>ObjectiveTo investigate the profile of circulatory renin-angiotensin system (RAS) activity in hypercholesterolemia (HC) patients treated with statins. Methods This study included 18 primary HC patients and 18 sex-and age-matched healthy adults. Total cholesterol (TC), triglyceride (TG), LDL-C and blood glucose, angiotensin-converting enzyme (ACE) activity and angiotensin II (AngII) levels were measured at baseline. These parameters were measured again at 4 and 8 weeks after statin treatment in HC group respectively. Results At baseline, the TC, TG and LDL-C, as well as ACE activity and AngII level, were significantly higher in HC group. On the baseline data of 36 participates, significant positive correlations existed between ACE activity and TC(r = 0.54) or LDL-C(r = 0.51), and between AngII level and TC(r = 0.34) or LDL-C(r = 0.27). In HC patients, 8 weeks statin treatment significantly decreased TC, LDL-C, as well as Ang II (35.46 ± 14.49 vs 71.10 ± 20.47 pg/ml, P < 0.05) levels and ACE activity (108.9 ± 51.9vs 180.1 ± 71.3 U/L, P < 0.05), meanwhile, positive correlations between RAS activity and TC or LDL-C levels measured before and after treatment were seen in HC patients. Conclusions Serum cholesterol-lowering with statins is associated with decreasing circulatory RAS activity in hypercholesterolemia patients.</description><identifier>ISSN: 1355-6037</identifier><identifier>EISSN: 1468-201X</identifier><identifier>DOI: 10.1136/heartjnl-2013-303992.240</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and British Cardiovascular Society</publisher><ispartof>Heart (British Cardiac Society), 2013-04, Vol.99 (Suppl 1), p.A77-A78</ispartof><rights>2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2013 (c) 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://heart.bmj.com/content/99/Suppl_1/A77.4.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://heart.bmj.com/content/99/Suppl_1/A77.4.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,780,784,3196,23571,27924,27925,77600,77631</link.rule.ids></links><search><creatorcontrib>Hai, Su</creatorcontrib><creatorcontrib>Weitong, Hu</creatorcontrib><creatorcontrib>Qiang, Peng</creatorcontrib><creatorcontrib>Dezhi, Hong</creatorcontrib><creatorcontrib>Jianyong, Ma</creatorcontrib><creatorcontrib>Qing, Yang</creatorcontrib><creatorcontrib>Xiaoshu, Cheng</creatorcontrib><title>ASSA13-16-6 The Increased Circulatory RAS Activity Can Be Inhibited by Statins</title><title>Heart (British Cardiac Society)</title><addtitle>Heart</addtitle><description>ObjectiveTo investigate the profile of circulatory renin-angiotensin system (RAS) activity in hypercholesterolemia (HC) patients treated with statins. Methods This study included 18 primary HC patients and 18 sex-and age-matched healthy adults. Total cholesterol (TC), triglyceride (TG), LDL-C and blood glucose, angiotensin-converting enzyme (ACE) activity and angiotensin II (AngII) levels were measured at baseline. These parameters were measured again at 4 and 8 weeks after statin treatment in HC group respectively. Results At baseline, the TC, TG and LDL-C, as well as ACE activity and AngII level, were significantly higher in HC group. On the baseline data of 36 participates, significant positive correlations existed between ACE activity and TC(r = 0.54) or LDL-C(r = 0.51), and between AngII level and TC(r = 0.34) or LDL-C(r = 0.27). In HC patients, 8 weeks statin treatment significantly decreased TC, LDL-C, as well as Ang II (35.46 ± 14.49 vs 71.10 ± 20.47 pg/ml, P < 0.05) levels and ACE activity (108.9 ± 51.9vs 180.1 ± 71.3 U/L, P < 0.05), meanwhile, positive correlations between RAS activity and TC or LDL-C levels measured before and after treatment were seen in HC patients. Conclusions Serum cholesterol-lowering with statins is associated with decreasing circulatory RAS activity in hypercholesterolemia patients.</description><issn>1355-6037</issn><issn>1468-201X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNkMtOwzAQRSMEEqXwD5FYp3gysZMsQwS0UsWrpWJn2YmrJrRJsV1Edmz4Ub4EVwHWrGY0OveOdDzPBzICQHaxUkLbulkHIQEMkGCahqMwIgfeACKW7M_Ph25HSgNGMD72ToypCSFRmrCBd5_NZpkLAgvY18fnfKX8SVNoJYwq_bzSxW4tbKs7_zGb-Vlhq7fKdn4uGv9yT64qWVlHys6fWWGrxpx6R0uxNursZw69p-ureT4Opnc3kzybBhJoGgUUQBYJiWlYhFQtMYGSEZFiGZcCISGKKWRlQspUEUEhFZFEySCViqJEEDj0zvverW5fd8pYXrc73biXHGJXHMY0ihyV9FShW2O0WvKtrjZCdxwI3_vjv_743h_v_XHnz0WDPloZq97_ckK_cBZjTPntIudjmF8v8IHyxPHY83JT___LNwyhgxY</recordid><startdate>201304</startdate><enddate>201304</enddate><creator>Hai, Su</creator><creator>Weitong, Hu</creator><creator>Qiang, Peng</creator><creator>Dezhi, Hong</creator><creator>Jianyong, Ma</creator><creator>Qing, Yang</creator><creator>Xiaoshu, Cheng</creator><general>BMJ Publishing Group Ltd and British Cardiovascular Society</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201304</creationdate><title>ASSA13-16-6 The Increased Circulatory RAS Activity Can Be Inhibited by Statins</title><author>Hai, Su ; Weitong, Hu ; Qiang, Peng ; Dezhi, Hong ; Jianyong, Ma ; Qing, Yang ; Xiaoshu, Cheng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1594-511bc80752c25ef381d60a93d7da3180e6e36d80d9e0a519a4b3b619be53b31a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hai, Su</creatorcontrib><creatorcontrib>Weitong, Hu</creatorcontrib><creatorcontrib>Qiang, Peng</creatorcontrib><creatorcontrib>Dezhi, Hong</creatorcontrib><creatorcontrib>Jianyong, Ma</creatorcontrib><creatorcontrib>Qing, Yang</creatorcontrib><creatorcontrib>Xiaoshu, Cheng</creatorcontrib><collection>Istex</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Heart (British Cardiac Society)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hai, Su</au><au>Weitong, Hu</au><au>Qiang, Peng</au><au>Dezhi, Hong</au><au>Jianyong, Ma</au><au>Qing, Yang</au><au>Xiaoshu, Cheng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ASSA13-16-6 The Increased Circulatory RAS Activity Can Be Inhibited by Statins</atitle><jtitle>Heart (British Cardiac Society)</jtitle><addtitle>Heart</addtitle><date>2013-04</date><risdate>2013</risdate><volume>99</volume><issue>Suppl 1</issue><spage>A77</spage><epage>A78</epage><pages>A77-A78</pages><issn>1355-6037</issn><eissn>1468-201X</eissn><abstract>ObjectiveTo investigate the profile of circulatory renin-angiotensin system (RAS) activity in hypercholesterolemia (HC) patients treated with statins. Methods This study included 18 primary HC patients and 18 sex-and age-matched healthy adults. Total cholesterol (TC), triglyceride (TG), LDL-C and blood glucose, angiotensin-converting enzyme (ACE) activity and angiotensin II (AngII) levels were measured at baseline. These parameters were measured again at 4 and 8 weeks after statin treatment in HC group respectively. Results At baseline, the TC, TG and LDL-C, as well as ACE activity and AngII level, were significantly higher in HC group. On the baseline data of 36 participates, significant positive correlations existed between ACE activity and TC(r = 0.54) or LDL-C(r = 0.51), and between AngII level and TC(r = 0.34) or LDL-C(r = 0.27). In HC patients, 8 weeks statin treatment significantly decreased TC, LDL-C, as well as Ang II (35.46 ± 14.49 vs 71.10 ± 20.47 pg/ml, P < 0.05) levels and ACE activity (108.9 ± 51.9vs 180.1 ± 71.3 U/L, P < 0.05), meanwhile, positive correlations between RAS activity and TC or LDL-C levels measured before and after treatment were seen in HC patients. Conclusions Serum cholesterol-lowering with statins is associated with decreasing circulatory RAS activity in hypercholesterolemia patients.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and British Cardiovascular Society</pub><doi>10.1136/heartjnl-2013-303992.240</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1355-6037 |
ispartof | Heart (British Cardiac Society), 2013-04, Vol.99 (Suppl 1), p.A77-A78 |
issn | 1355-6037 1468-201X |
language | eng |
recordid | cdi_proquest_journals_1780727544 |
source | PubMed Central Free; BMJ Journals - NESLi2 |
title | ASSA13-16-6 The Increased Circulatory RAS Activity Can Be Inhibited by Statins |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T06%3A44%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ASSA13-16-6%E2%80%85The%20Increased%20Circulatory%20RAS%20Activity%20Can%20Be%20Inhibited%20by%20Statins&rft.jtitle=Heart%20(British%20Cardiac%20Society)&rft.au=Hai,%20Su&rft.date=2013-04&rft.volume=99&rft.issue=Suppl%201&rft.spage=A77&rft.epage=A78&rft.pages=A77-A78&rft.issn=1355-6037&rft.eissn=1468-201X&rft_id=info:doi/10.1136/heartjnl-2013-303992.240&rft_dat=%3Cproquest_cross%3E4021078231%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1780727544&rft_id=info:pmid/&rfr_iscdi=true |